P. «. Fenaux, Myelodysplastic syndromes, Myelodysplastic syndromes, pp.363-80, 1996.
DOI : 10.1007/s00282-996-0363-7

URL : https://hal.archives-ouvertes.fr/hal-00127375

E. Levine and C. Bloomfield, « Leukemia and myelodysplastic syndromes secondary to drug, radiation, and environnemental exposure, Semin Oncol, vol.19, issue.1, pp.47-84, 1992.

S. Strom, Y. Gu, S. Gruschkus, S. Pierce, and E. Estey, Risk factors of myelodysplastic syndromes: a case???control study, Leukemia, vol.73, issue.11, pp.1912-1918, 2005.
DOI : 10.1136/oem.59.9.575

R. West, D. Stafford, A. Farrow, and A. Jacobs, Occupational and environmental exposures and myelodysplasia: A case-control study, Leukemia Research, vol.19, issue.2, pp.127-139, 1995.
DOI : 10.1016/0145-2126(94)00141-V

J. Björk, M. Albin, N. Mauritzson, U. Strömberg, B. Johansson et al., Smoking and Myelodysplastic Syndromes, Smoking and Myelodysplastic Syndromes, pp.285-291, 2000.
DOI : 10.1097/00001648-200005000-00010

Y. Du, J. Fryzek, M. Sekeres, and E. Taioli, Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS), Leukemia Research, vol.34, issue.1, pp.1-5, 2010.
DOI : 10.1016/j.leukres.2009.08.006

M. Ido, C. Nagata, and N. Kawakami, A case-control study of myelodysplastic syndromes among Japanese men and women, Leukemia Research, vol.20, issue.9, pp.727-731, 1996.
DOI : 10.1016/0145-2126(96)00042-2

C. Nagata, H. Shimizu, and K. Hirashima, Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome, Leukemia Research, vol.23, issue.1, pp.57-62, 1999.
DOI : 10.1016/S0145-2126(98)00135-0

M. Albin, J. Björk, and H. Welinder, Cytogenetic and morphologic subgroups of myelodysplastic syndromes in relation to occupational and hobby exposures, Scandinavian Journal of Work, Environment & Health, vol.29, issue.5, pp.378-387, 2003.
DOI : 10.5271/sjweh.744

A. Tefferi and J. Vardiman, Myelodysplastic Syndromes, Myelodysplastic Syndromes, pp.1872-1885, 2009.
DOI : 10.1056/NEJMra0902908

M. Tormo, I. Marugan, and M. Calabuig, Myelodysplastic syndromes: an update on molecular pathology, Clinical and Translational Oncology, vol.144, issue.10, pp.652-661, 2010.
DOI : 10.1007/s12094-010-0574-9

B. «. Baylin, DNA methylation and gene silencing in cancer, Nature Clinical Practice Oncology, vol.249, issue.1, pp.4-11, 2005.
DOI : 10.1038/ncponc0354

Y. Jiang, A. Dunbar, and L. Gondek, Aberrant DNA methylation is a dominant mechanism in MDS progression to AML, Blood, vol.113, issue.6, pp.1315-1325, 2009.
DOI : 10.1182/blood-2008-06-163246

J. Boultwood, S. Lewis, and J. S. Wainscoat, 5q- syndrome, Current Pharmaceutical Design, vol.18, issue.22, pp.3253-3260, 1994.
DOI : 10.2174/1381612811209023180

E. M. Sloand and K. Rezvani, The Role of the Immune System in Myelodysplasia: Implications for Therapy, Seminars in Hematology, vol.45, issue.1, pp.39-48
DOI : 10.1053/j.seminhematol.2007.11.006

J. W. Vardiman, J. Thiele, and D. A. Arber, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.
DOI : 10.1182/blood-2009-03-209262

J. M. Bennett, D. Catovsky, and M. T. Daniel, Proposals for the classification of the myelodysplastic syndromes, British Journal of Haematology, vol.92, issue.2, pp.189-199, 1982.
DOI : 10.1016/0145-2126(79)90006-7

U. Germing, N. Gatterman, C. Strupp, M. Aivado, and C. Aul, Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients, Leukemia Research, vol.24, issue.12, pp.983-992, 2000.
DOI : 10.1016/S0145-2126(00)00088-6

R. B. Howe, A. Porwitt-macdonald, R. Wanat, R. Tehranchi, and E. Hellström-lindberg, The WHO classification of MDS does make a difference, Blood, vol.103, issue.9, pp.3265-3270, 2004.
DOI : 10.1182/blood-2003-06-2124

J. W. Vardiman, L. Harris, N. Brunning, and R. «. , The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-2302, 2002.
DOI : 10.1182/blood-2002-04-1199

L. Malcovati, D. Porta, M. G. Pascutto, and C. , Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making, Journal of Clinical Oncology, vol.23, issue.30, pp.7594-7603, 2005.
DOI : 10.1200/JCO.2005.01.7038

B. D. Cheson, P. L. Greenberg, and J. M. Bennett, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, vol.108, issue.2, pp.419-425, 2006.
DOI : 10.1182/blood-2005-10-4149

S. Park, S. Grabar, and C. Kelaidi, Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience, Blood, vol.111, issue.2, pp.574-582, 2008.
DOI : 10.1182/blood-2007-06-096370

B. L. Scott and E. Estey, « Management of Myelodysplastic Syndromes, Update ». Oncology, vol.22, issue.12, pp.1344-1368, 2008.

M. Jädersten, L. Malcovati, and I. Dybedal, Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome, Journal of Clinical Oncology, vol.26, issue.21, pp.3607-3613, 2008.
DOI : 10.1200/JCO.2007.15.4906

A. List, S. Kurtin, and D. J. Roe, Efficacy of Lenalidomide in Myelodysplastic Syndromes, Efficacy of Lenalidomide in Myelodysplastic Syndromes, pp.549-557, 2005.
DOI : 10.1056/NEJMoa041668

A. List, G. Dewald, and J. Bennett, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion, pp.1456-1465, 2006.
DOI : 10.1056/NEJMoa061292

J. J. Molldrem, E. Leifer, and E. Bahceci, Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes, Annals of Internal Medicine, vol.137, issue.3, pp.156-163, 2002.
DOI : 10.7326/0003-4819-137-3-200208060-00007

H. Kantarjian, J. J. Issa, and C. S. Rosenfeld, Decitabine improves patient outcomes in myelodysplastic syndromes, Decitabine Improves Patients Outcomes in Myelodysplastic Syndromes, pp.1794-1803, 2006.
DOI : 10.1002/cncr.21792

P. Fenaux, G. Mufti, and E. Hellstrom-lindberg, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, The Lancet Oncology, vol.10, issue.3, pp.223-232, 2009.
DOI : 10.1016/S1470-2045(09)70003-8

G. Garcia-monero and P. Fenaux, Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.29, issue.5, pp.516-523, 2011.
DOI : 10.1200/JCO.2010.31.0854

M. A. Siddiqui, L. J. Scott, and . Azacitidine, Azacitidine, Myelodysplastic Syndromes, pp.1781-1789, 2005.
DOI : 10.2165/00003495-200565130-00004

C. Stresemann and F. Lyko, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, International Journal of Cancer, vol.35, issue.1, pp.8-13, 2008.
DOI : 10.1002/ijc.23607

G. Marcucci, L. Silverman, M. Eller, L. Lintz, and C. L. Beach, Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes, The Journal of Clinical Pharmacology, vol.41, issue.5, pp.597-602, 2005.
DOI : 10.1177/0091270004271947

Y. W. Cheung, B. R. Vishnuvajjala, N. L. Morris, and K. P. Flora, « Stability of azacitidine in infusion fluids », Am J Hosp Pharm, vol.41, issue.6, pp.1156-1159, 1984.

A. Duriez, J. H. Vigneron, H. A. Ziener, I. May, and B. M. Demoré, « Stability of Azacitidine Suspensions ». The annals of Pharmacotherapy, p.546, 2011.

L. R. Silverman, E. P. Demakos, and L. Bercedis, Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B, Journal of Clinical Oncology, vol.20, issue.10, pp.2429-2440, 2002.
DOI : 10.1200/JCO.2002.04.117

A. B. Kornblith, J. E. Herndon, and E. P. Demakos, Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.20, issue.10, pp.2441-2452, 2002.
DOI : 10.1200/JCO.2002.04.044

P. Musto, L. Maurillo, and A. Spagnoli, Azacitidine for the treatment of lower risk myelodysplastic syndromes, Cancer, vol.15, issue.6, pp.1485-1494, 2010.
DOI : 10.1002/cncr.24894

R. M. Lyons, T. M. Cosgriff, and S. S. Modi, Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.27, issue.11, pp.1850-1856, 2009.
DOI : 10.1200/JCO.2008.17.1058

J. F. Seymour, P. Fenaux, and L. R. Silverman, Effects of azacitidine compared with conventional care regimens in elderly (???75 years) patients with higher-risk myelodysplastic syndromes, Critical Reviews in Oncology/Hematology, vol.76, issue.3, pp.218-227, 2010.
DOI : 10.1016/j.critrevonc.2010.04.005

T. Field, J. Perkins, and M. Alsina, Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogenic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodyspalstic Syndrome, MDS) ». Blood (ASH Annual Meeting Abstracts, 2006.

G. E. Vigil, T. Martin-santos, and G. Garcia-manero, Safety and efficacy of azacitidine in myelodysplastic syndromes, Drug Design, Development and Therapy, vol.4, issue.4, pp.221-229, 2010.
DOI : 10.2147/DDDT.S3143

M. Lima, L. Padua, and S. Giralt, A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-azacitidine (AZA) after Allogenic Hemtopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS, Blood (ASH Annual Meeting Abstracts, 2007.

J. M. Rossetti, R. K. Shadduck, C. Thatikonda, E. Sahovic, and J. Lister, « Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation, Blood (ASH Annual Meeting Abstracts, 2007.

Y. Chen, L. Liu, E. Laille, G. Kumar, and S. Surapaneni, In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine, Cancer Chemotherapy and Pharmacology, vol.30, issue.1, pp.995-1000, 2010.
DOI : 10.1007/s00280-010-1245-9

G. Garcia-manero, S. Gore, and B. Skikne, A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes, MDS) or Acute Myelogenous Leukemia (AML) ». Blood (ASH Annual Meeting Abstracts, 2009.

M. T. Voso, V. Santini, and C. Finelli, Valproic Acid at Therapeutic Plasma Levels May Increase 5-azactidine Efficacy in High Risk Myelodysplastic Syndromes, Cancer Ther, vol.15, issue.15, pp.5002-5007, 2009.

L. R. Silverman, A. Verma, and R. Odchimar-reissig, A phase I/II study of vorinostat an oral histone deacétylases inhibitor, in combonation with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) Initial results of the phase I trial: A New York Cancer Consortium, JCO, vol.26, 2008.

G. Garcia-monero, S. Assouline, and J. Cortes, Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia, Blood, vol.112, issue.4, pp.981-989, 2008.
DOI : 10.1182/blood-2007-10-115873

M. A. Sekeres, A. F. List, and D. Cuthbertson, Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Highter-Risk Myelodysplastic Syndromes (MDS), Blood. (ASH Annual Meeting Abstracts), vol.112, 2008.

A. Raza, M. Mehdi, M. Mumtaz, F. Ali, S. Lascher et al., Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia, Cancer, vol.84, issue.7, pp.1596-1604, 2008.
DOI : 10.1002/cncr.23789

B. L. Scott, A. Ramakrishnan, and B. Storer, Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept, British Journal of Haematology, vol.100, issue.6, pp.944-947, 2010.
DOI : 10.1111/j.1365-2141.2009.08061.x

. V. Santini, . P. Fenaux, . Mufti, and . Gj, Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*, European Journal of Haematology, vol.26, issue.2, pp.130-138, 2010.
DOI : 10.1111/j.1600-0609.2010.01456.x

K. Götze, U. Platzbecker, and A. Giaagounidis, Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group, Annals of Hematology, vol.112, issue.Suppl 1, pp.841-850, 2010.
DOI : 10.1007/s00277-010-1015-0

C. Seynaeve, J. Schuller, and K. Buser, Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study, British Journal of Cancer, vol.66, issue.1, pp.192-197, 1992.
DOI : 10.1038/bjc.1992.241

R. M. Navari, S. Madajewicz, and N. Anderson, Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo., Journal of Clinical Oncology, vol.13, issue.9, pp.2408-2416, 1995.
DOI : 10.1200/JCO.1995.13.9.2408

L. R. Silverman, D. R. Mckenzie, and B. L. Peterson, Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, Journal of Clinical Oncology, vol.24, issue.24, pp.3895-3903, 2006.
DOI : 10.1200/JCO.2005.05.4346

B. A. Peterson, A. J. Collins, N. J. Vogelzang, and C. D. Bloomfield, « 5-Azacytidine and Renal Tubular Dysfunction, Blood, vol.57, issue.1, pp.182-185, 1981.

D. Lima, M. De-padua-silva, L. Giralt, and S. , Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogenic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study, Blood (ASH Annual Meeting Abstracts, 2008.

C. N. Hueser and A. J. Patel, Azacitidine-Associated Hyperthermia and Interstitial Pneumonitis in a Patient with Myelodysplastic Syndrome, Pharmacotherapy, vol.165, issue.2, pp.1759-1762, 2007.
DOI : 10.1001/jama.280.2.159

A. Sekhri, C. Palaniswamy, K. Kurmayagari, A. Kalra, and D. R. Selvaraj, Interstitial Lung Disease Associated With Azacitidine Use, American Journal of Therapeutics, vol.19, issue.2
DOI : 10.1097/MJT.0b013e3181e7a526

C. D. Adams, P. M. Szumita, S. A. Baroletti, and C. M. Lilly, Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient with Myelodysplastic Syndrome, Pharmacotherapy, vol.41, issue.2, pp.765-768, 2005.
DOI : 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q

E. French, Tiré du site http://groups.eortc.be/qol, 2001.

N. K. Aaronson, S. Ahmedzai, and B. Bergman, The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-376, 1993.
DOI : 10.1093/jnci/85.5.365

E. «. Eortc-qlq-c30-scoring and . Manual, Tiré du site http://groups.eortc.be, 3ème édition, 2001.

S. Sweetman, W. Martindale, and . Azacitidine, Martindale: The complete drug reference-36 th Ed, pp.683-684, 2009.

A. Vidaza®, Tiré du site www.afssaps.fr, Résumé des caractéristiques du produit, p.12, 2008.